These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 7755506)

  • 21. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virus-specific cytotoxic T lymphocyte responses in patients infected with the human immunodeficiency virus, HIV-1.
    Rivière Y
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():45-8. PubMed ID: 7950861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector.
    Frankel FR; Hegde S; Lieberman J; Paterson Y
    J Immunol; 1995 Nov; 155(10):4775-82. PubMed ID: 7594479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alloactivated cytotoxic T cells recognize the carboxy-terminal domain of human immunodeficiency virus-1 gp120 envelope glycoprotein.
    Clerici M; Shearer G; Hounsell EF; Jameson B; Habeshaw J; Dalgleish AG
    Eur J Immunol; 1993 Aug; 23(8):2022-5. PubMed ID: 8344368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques.
    Wagner R; Deml L; Notka F; Wolf H; Schirmbeck R; Reimann J; Teeuwsen V; Heeney J
    Intervirology; 1996; 39(1-2):93-103. PubMed ID: 8957675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
    Marsac D; Loirat D; Petit C; Schwartz O; Michel ML
    J Virol; 2002 Aug; 76(15):7544-53. PubMed ID: 12097567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector.
    Carbonetti NH; Tuskan RG; Lewis GK
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):819-27. PubMed ID: 11429123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    Hammond SA; Bollinger RC; Stanhope PE; Quinn TC; Schwartz D; Clements ML; Siliciano RF
    J Exp Med; 1992 Dec; 176(6):1531-42. PubMed ID: 1460417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions.
    Ghunaim H; Kumar A; Torres J; Diaz-Mitoma F; Azizi A
    Vaccine; 2011 Aug; 29(35):5950-8. PubMed ID: 21718739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
    Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
    Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
    Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of HIV persistence: implications for vaccines and therapy.
    Bremermann HJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(5):459-83. PubMed ID: 7627623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).
    Shearer GM; Bernstein DC; Tung KS; Via CS; Redfield R; Salahuddin SZ; Gallo RC
    J Immunol; 1986 Oct; 137(8):2514-21. PubMed ID: 3489767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.
    Layton GT; Harris SJ; Gearing AJ; Hill-Perkins M; Cole JS; Griffiths JC; Burns NR; Kingsman AJ; Adams SE
    J Immunol; 1993 Jul; 151(2):1097-107. PubMed ID: 8335892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QUASI analysis of host immune responses to Gag polyproteins of human immunodeficiency virus type 1 by a systematic bioinformatics approach.
    Liang B; Luo M; Ball TB; Jones SJ; Plummer FA
    Biochem Cell Biol; 2010 Aug; 88(4):671-81. PubMed ID: 20651839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic T lymphocytes in HIV-induced disease: implications for therapy and vaccination.
    Plata F; Dadaglio G; Chenciner N; Hoffenbach A; Wain-Hobson S; Michel F; Langlade-Demoyen P
    Immunodefic Rev; 1989; 1(3):227-46. PubMed ID: 2698642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic T-cell recognition of HIV proteins and peptides.
    Nixon DF; McMichael AJ
    AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.